Novo Nordisk
United States
1217 articles about Novo Nordisk
-
Novo Nordisk will take over Prothena's wholly-owned subsidiary and gain full global intellectual property rights and other related rights for the latter's ATTR amyloidosis business and pipeline.
-
Clinical Catch-Up: June 28-July 2
7/6/2021
It was another busy week for clinical trial news ahead of the July 4 holiday in the U.S. Here’s a look. -
Three partnerships were signed today between biopharmaceutical and therapeutics companies in a bid to develop treatment for major diseases with high mortality rates.
-
Eli Lilly and Novo Nordisk published their data in The Lancet Diabetes & Endocrinology and presented them at the ADA conference.
-
This program limits the prices drug manufacturers can charge for therapies sold to specific healthcare facilities, including public hospitals and community health centers.
-
Novo Nordisk to present research across diabetes and obesity portfolio at the 81st Annual American Diabetes Association Scientific Sessions
6/16/2021
Novo Nordisk announced that new data from more than 30 abstracts will be presented from the company's approved and investigational medicines highlighting its broad diabetes and obesity portfolio at the upcoming 81st Annual Scientific Sessions of the American Diabetes Association.
-
Lumen Bioscience and Novo Nordisk Enter into Research Collaboration to Explore Novel Strategies to Deliver Oral Biologics for Cardiometabolic Disease
6/16/2021
Lumen Bioscience announced today it has entered into a research collaboration with Novo Nordisk to evaluate the use of Lumen's unique drug development and manufacturing platform in Novo Nordisk's research and development activities within obesity and other metabolic disorders.
-
Seattle-based clinical-stage biopharmaceutical company Lumen Bioscience is teaming up with Novo Nordisk to explore research and development opportunities within obesity, among other metabolic disorders.
-
Novo Nordisk's Wegovy is First and Only Once-Weekly GLP-1 Agonist Approved for Weight Management
6/7/2021
Wegovy is the first and only once-weekly GLP-1 receptor agonist that’s been approved for weight control in people living with obesity. This is the same drug used to treat type 2 diabetes. -
Novo Nordisk receives FDA approval for Wegovy™ to treat adults with obesity based on unprecedented efficacy for a prescription medicine in clinical trials
6/4/2021
- Despite being recognized by leading authorities as a serious disease, obesity remains stigmatized, resulting in patients being underdiagnosed and significantly undertreated - Approval includes results from STEP 1, a clinical trial where once-weekly, prescription GLP-1 receptor agonist Wegovy™ (semaglutide) injection 2.4 mg, demonstrated an average weight loss of ~15% at 68-weeks when used with a reduced calorie meal plan and increased physical activity
-
BioSpace takes an in-depth look at the Top 25 of Q1. You should be aware of these biopharma companies as they hold a great future ahead. So, check them out.
-
Executives at pharmaceutical companies are known for receiving large salaries. When bonuses and stock options are factored into the picture, their annual compensation can jump into the range of tens of millions of dollars, like Pfizer’s Albert Bourla, Alex Gorsky from Johnson & Johnson, and Astra...
-
Novo Nordisk and TetraScience partner on a cloud-based instrument data platform
3/23/2021
Novo Nordisk A/S, a leading global healthcare company, and TetraScience, the leading global Life Sciences R&D Data Cloud, announce a new partnership to design a cloud-based instrument data platform for drug R&D, built natively on Amazon Web Services.
-
Adults with obesity treated with semaglutide 2.4 mg achieved and maintained a significant amount of weight loss in a 68-week trial
3/23/2021
Data presented at ENDO 2021 demonstrate clinically relevant weight loss, without weight regain, in people treated with semaglutide 2.4 mg vs placebo in combination with lifestyle intervention
-
The life sciences industry is a bustling beehive of activity. Here’s a quick compilation of some of today’s newsworthy announcements.
-
Clinical Catch-Up: March 15-19
3/22/2021
It was a relatively quiet week in terms of clinical trial news, but there were some significant releases. Here’s a look. -
Gilead and Novo Nordisk Expand NASH Clinical Collaboration
3/18/2021
Gilead Sciences, Inc. and Novo Nordisk A/S announced that the companies have expanded their clinical collaboration in non-alcoholic steatohepatitis.
-
It will evaluate about 440 patients and the treatments’ effect on liver fibrosis improvement and NASH resolution.
-
Lilly’s tirzepatide has been proposed as a potentially effective treatment option that may rival the efficacy of semaglutide.
-
City of Mississauga welcomes new research hub in Mississauga funded by Novo Nordisk and University of Toronto aimed at reducing diabetes in community
2/25/2021
Yesterday, Novo Nordisk a global healthcare company with Canadian headquarters in Mississauga, and the University of Toronto announced a new research hub at U of T's Mississauga campus that will bring leading public health experts together to help reduce chronic illnesses across the globe.